Backed by $40M, a biotech startup targets cancer with help from the immune system
BioPharma
Stay updated with breaking news from Lightspeed Venture. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Artificial intelligence and machine learning are key to 3T Biosciences’ approach to identifying novel drug targets and engineering better, safer cancer immunotherapies. The Stanford spinout is now out of stealth with a $40 million Series A financing and a plan to reach the clinic within two years.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
One investor, who declined to be named for fear of alienating peers, said the rapid food delivery business was "going to be a f***ing bloodbath."